Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Premarin Memory Data Mixed On Dementia Risk; 91% Of Rxs For Menopause

Executive Summary

Prescriptions for Wyeth's Prempro and Premarin have almost completely shifted to the relief of vasomotor symptoms in the two years since the first publication of negative findings from the Women's Health Initiative

You may also be interested in...

Premarin WHI Results Support Short-Term Use, Wyeth And Investigators Agree

Results of the Premarin arm of the Women's Health Initiative study confirm clinical recommendations that hormone therapy should not be used for long-term chronic disease prevention

Premarin WHI Results May Mean Additional Labeling Changes, FDA Says

FDA may request additional changes to the labeling of hormone replacement therapies based on the findings from the terminated Premarin arm of the Women's Health Initiative

Hormone Therapy Dementia “Black Box” Warning Sought By FDA

FDA is recommending a hormone replacement therapy class "black box" warning on an increased risk of dementia with use of estrogen and combination estrogen/progestin products

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts